Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS
ÌÇÐÄ´«Ã½
HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., Jacobson, I., Tran, T. T., Nahass, R., Hinestrosa, F., Herring, R., Bennet, M., Yang, J. C., Stamm, L. M., An, D., Dvory-Sobol, H., Brainard, D. M., McHutchison, J. G., Schiff, E., Davis, M., Etzkorn, K., Chung, R. T., Pound, D., Rodriguez-Torres, M., Reddy, K. R., Younes, Z., Gane, E. J. ELSEVIER SCIENCE BV. 2016: S139–S140View details for
View details for